Propylhexedrine

# Research Output: Propylhexedrine

## Chemical Identity

**Verified via PubChem CID 7558 [Ref 22] and cross-referenced with HandWiki [Ref 22]:**

- **PubChem CID:** 7558
- **IUPAC name:** 1-cyclohexyl-N-methylpropan-2-amine (matches brief seed data)
- **Canonical SMILES:** N(C(CC1CCCCC1)C)C (freebase)
- **InChIKey:** JCRIVQIOJSSCQD-UHFFFAOYSA-N
- **Molecular formula:** C₁₀H₂₁N
- **Molecular weight:** 155.28 g/mol
- **CAS number (freebase):** 101-40-6
- **CAS number (hydrochloride):** 1007-33-6

**Physical properties [Ref 22]:**
- Freebase propylhexedrine is a volatile, oily liquid at room temperature with a characteristic amine odor — this is the form used in Benzedrex inhalers (the cotton rod is saturated with the freebase liquid).
- Hydrochloride salt appears as off-brown/white crystals, water-soluble.
- The compound contains one chiral center.

**Discrepancies with seed data:**
- The seed data had blank fields for SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID — all now confirmed above.
- The brief correctly identifies systematic name as 1-cyclohexyl-N-methylpropan-2-amine.

---

## Pharmacology

### Mechanism of Action

Propylhexedrine operates by a dose-dependent, route-dependent dual mechanism [Ref 17, Ref 22, Ref 25]:

**At therapeutic inhaler doses:**
Propylhexedrine acts primarily as a direct **alpha-adrenergic receptor agonist**, producing local vasoconstriction in nasal mucosa. At these concentrations it minimally penetrates the CNS. It relieves nasal congestion without significant rebound rhinitis (Wesson 1986 [Ref 25]).

**At recreational/abuse doses (oral ingestion or intravenous):**
Propylhexedrine acts as a **norepinephrine–dopamine releasing agent (NDRA)**, reversing the norepinephrine transporter (NET) and dopamine transporter (DAT) to pump monoamines from cytosol into the synapse. Secondary mechanisms include **TAAR1 agonism** and **VMAT2 inhibition**, both of which further amplify cytosolic monoamine pools [Ref 22]. Serotonin release has also been described (SNDRA), though norepinephrine and dopamine are the primary effectors [Ref 22, Ref 17].

**Selectivity and comparative potency:**
In a pigeon drug discrimination study, propylhexedrine (10–100 mg/kg) only partially substituted for d-amphetamine (generalized in 2/3 birds), indicating partial amphetamine-like discriminative stimulus properties at high doses and suggesting lower CNS potency relative to amphetamine (Evans & Johanson 1987 [Ref 6]). Wesson's WHO Expert Committee review (1986 [Ref 25]) confirmed propylhexedrine is a CNS stimulant of **low abuse potential relative to amphetamine, methylphenidate, and phenmetrazine**, with low preference among stimulant abusers when alternatives are available.

**Specific receptor binding data (Ki/EC50):**
No published peer-reviewed study providing quantitative binding affinity data (Ki, EC50, or IC50 at NET, DAT, SERT, or adrenergic receptor subtypes) specific to propylhexedrine was identified in PubMed, OpenAlex, or available secondary databases. This is a **significant gap** flagged for the generation agent. The WADA pharmacology review (Docherty 2008 [Ref 8]) discusses class-level mechanisms for stimulants but does not provide propylhexedrine-specific quantitative binding data.

### Pharmacokinetics

**Half-life:**
The pharmacokinetic elimination half-life is approximately **4 ± 1.5 hours** in humans (HandWiki [Ref 22], citing secondary sources), though variability exists based on urinary pH and CYP activity. In a mouse study using the barbexaclone salt formulation, Iven & Feldbusch (1983 [Ref 14]) determined: t½α = 0.31 h (distribution phase), t½β = 2.5 h (elimination phase), Vd = 19.3 L/kg.

**Bioavailability:**
Oral bioavailability estimated at ~37% in mice (AUC oral/AUC IV = 0.37) (Iven & Feldbusch 1983 [Ref 14]). No published human bioavailability data found.

**Tissue distribution:**
High and unequal tissue accumulation in mice: lung = kidney > liver = brain > spleen > heart > skeletal muscle. Propylhexedrine rapidly penetrates the blood–brain barrier (Iven & Feldbusch 1983 [Ref 14]). Hair incorporation data indicates the cyclohexyl ring shows lower melanin affinity and higher lipophilicity than the phenyl ring of methamphetamine (Nakahara & Hanajiri 2000 [Ref 16]).

**Metabolism:**
Propylhexedrine is metabolized via multiple pathways: N-demethylation, C-oxidation, N-oxidation, dehydrogenation, and hydrolysis. Major metabolites include [Ref 22]:
- Norpropylhexedrine (N-demethylation)
- Cyclohexylacetoxime (N-oxidation/hydrolysis)
- Cyclohexylacetone (dehydrogenation)
- cis- and trans-4-hydroxypropylhexedrine (ring hydroxylation)

**CYP enzymes:** Specific CYP isoforms responsible for propylhexedrine metabolism are mentioned in secondary sources as "CYP enzymes" without specification of isoforms. No primary pharmacokinetic study naming specific CYP isoforms was identified in the published literature. This is a **gap flagged for editorial review.**

**Excretion:**
Excreted renally. Urinary pH significantly affects excretion rate (acidic urine accelerates clearance). No human urinary excretion fraction data found.

**Stereospecificity:**
Propylhexedrine exists as a **racemic mixture** (dl-propylhexedrine) in the Benzedrex inhaler. The **S-isomer (l-propylhexedrine, levopropylhexedrine)** is considered the more biologically active stereoisomer [Ref 22]. No published binding affinity comparisons between enantiomers in peer-reviewed literature were identified.

**Important distinction from seed data tolerance half-life:**
The seed data lists "Half-life: 5 days" under tolerance data — this refers to **pharmacodynamic tolerance decay**, not elimination half-life. The elimination half-life is 4 ± 1.5 hours (human estimate) or 2.5 hours (mouse elimination phase). These are not contradictory data points.

### Analytical Detection

Propylhexedrine's base-peak ion in GC/MS (HFBA derivatization) is identical to methamphetamine (m/z 254 amu), creating a risk of **false-positive methamphetamine drug screens** (Thurman et al. 1992 [Ref 19]). A specific ion table for ring-structure fragments is required to distinguish propylhexedrine from methamphetamine. The heptafluorobutyryl (HFB) derivative is the standard analytical method for quantitative determination in postmortem specimens (Holler et al. 2011 [Ref 1]).

---

## History

**Discovery and Synthesis:**
Propylhexedrine was synthesized by Dr. Glenn E. Ullyot and patented in 1948 for Smith, Kline & French (SK&F) [web sources verified via historical records]. The synthesis route involves **catalytic hydrogenation of methamphetamine over Adams' catalyst**, converting the aromatic phenyl ring to a saturated cyclohexyl ring — effectively replacing the pharmacological potency and CNS-penetrating aromaticity of methamphetamine with a more peripherally selective compound [Ref 22].

**Commercial Introduction:**
Market trials began in California on July 15, 1949. Propylhexedrine (as Benzedrex®) was first introduced into national commerce on August 4, 1949 by Smith, Kline & French, **replacing amphetamine sulfate** which had been withdrawn from over-the-counter Benzedrine inhalers due to widespread abuse, reports of psychosis, and sudden death (Fornazzari et al. 1986 [Ref 11]; Fernandez & Francis 2012 [Ref 9]). The name "Benzedrex" had been trademarked by SK&F since 1944.

**Clinical/Medical Use:**
Beyond its primary use as a nasal decongestant, propylhexedrine was also marketed **as an anorectic (appetite suppressant)**, particularly in some regions. One case of pulmonary hypertension developed after 8 years of oral propylhexedrine hydrochloride use as an anorectic (Cameron et al. 1984 [Ref 12]).

In Europe, propylhexedrine was incorporated into **barbexaclone**, a co-crystal/salt of propylhexedrine and phenobarbital used as an anticonvulsant. Multiple clinical trials demonstrated effective seizure control in epileptic patients (Reis et al. 1980 [Ref 27]; Oliveira et al. 1978). Barbexaclone abuse has been documented in a cannabis ex-user (Darcin et al. 2010 [Ref 26]).

**WHO Expert Committee Review:**
In the mid-1980s, growing concerns over abuse potential and propylhexedrine's use as a precursor for higher-potency compounds prompted the WHO Expert Committee on Drug Dependence to review the substance (Wesson 1986 [Ref 25]). The review concluded propylhexedrine has **low abuse potential relative to amphetamine, methylphenidate, and phenmetrazine**, and low preference among stimulant abusers. International scheduling under the Convention on Psychotropic Substances was not recommended at that time.

**Regulatory History:**
- 1988: Placed on Schedule V (US Controlled Substances Act)
- 1991: Removed from US Schedule V; international control reversed simultaneously
- 1995: Deregulated in the UK (removed from Misuse of Drugs Act 1971 via 1995 Modification Order)
- 2021: FDA Drug Safety Communication issued warning of serious harm from abuse/misuse
- 2022: Removed from Canada's Controlled Drugs and Substances Act (Schedule V)

**Resurgence of Abuse:**
While the first wave of documented IV abuse peaked in the 1970s–1980s, propylhexedrine has experienced a documented resurgence since approximately 2011, with annual poison control center cases rising from 11 (2011) to 74 (2019) (FDA 2021 [Ref 29]; Teja et al. 2020 [Ref 17]). Online communities and low retail price (\<$10 per inhaler) have contributed to accessibility (Teja et al. 2020 [Ref 17]).

---

## Subjective Effects

**Note:** No controlled human studies administering known doses of propylhexedrine and systematically evaluating subjective effects have been published. The following characterizations derive from published case series, adverse event descriptions, and comparative pharmacology.

**Stimulant effects at abuse doses (60–250+ mg oral or equivalent):**
Published case reports and review literature describe the following subjective and observed effects consistent with CNS stimulant activity:
- Euphoria and mood elevation (documented in abuse context) [Ref 9, Ref 17]
- Marked stimulation, wakefulness, decreased appetite [Ref 25, Ref 17]
- Increased heart rate and palpitations [Ref 29, Ref 21]
- Heightened anxiety, agitation, and restlessness [Ref 29]
- Paranoia, hallucinations, psychosis (reported with both IV and oral abuse) [Ref 11, Ref 9, Ref 29]
- Bruxism and muscle tension (class effect of stimulants; not specifically documented in propylhexedrine-specific studies)
- Sexual arousal changes (class effect; no substance-specific published data)

**Neurological effects with IV use:**
Transient diplopia occurring within seconds of IV injection (7 patients), internuclear ophthalmoplegia, depressed gag reflex, and hemitongue paralysis (Fornazzari et al. 1986 [Ref 11]). Some brainstem deficits persisted for months. Oral misuse produced neurological impairment with abnormal MRI findings in a 2024 case report (Horowitz et al. 2024 [Ref 2]).

**Duration profile (from seed data — community-derived, no controlled study source):**
The dose and duration data in the brief are sourced from community consensus rather than controlled clinical studies. The pharmacokinetic elimination half-life of ~4 hours (and potentially longer with alkaline urine) is consistent with the reported 4–10 hour total duration.

**Effect modifiers:**
- Urinary pH affects duration significantly: alkaline urine (e.g., dietary baking soda use, which is reportedly practiced by some users to extend effects) prolongs half-life; acidic urine accelerates clearance.
- Oral route of abuse involves the user extracting the propylhexedrine-saturated cotton from the inhaler and swallowing it or dissolving the compound in an acidic solution.

---

## Safety & Toxicity

### Acute Toxicity

**Postmortem blood concentrations in fatal cases:**
- 1.7 mg/L: propylhexedrine toxicity (cause of death), with mitragynine as possible contributing factor (Holler et al. 2011 [Ref 1])
- 3.75 mg/L: suspected fatal intoxication (Raudonat & Schmidt 1989 [Ref 4])

No LD50 data for humans. No formal human therapeutic index calculated from published data.

**FDA aggregate data (1969–2020) [Ref 29]:**
- 460 poison control cases involving propylhexedrine abuse (2000–2019)
- 21 cases with life-threatening adverse effects (poison control data)
- 13 cases required ICU admission
- Among 60 serious FDA FAERS reports: 23 life-threatening/hospitalized, 9 deaths
  - 6 of 9 deaths involved propylhexedrine combined with other substances
  - 1 death attributed to propylhexedrine alone
- Medical literature total: 49 case reports + 1 observational study; 18 deaths documented

### Cardiovascular Toxicity (Major Risk)

**Intravenous abuse (severe):**
Anderson et al. (1979 [Ref 28]) documented 15 propylhexedrine-related deaths in Dallas County since 1973; 12 from IV abuse. Autopsy findings consistently included:
- **Pulmonary edema**
- **Foreign body granulomas** (from cotton fibers and excipients injected with propylhexedrine)
- **Pulmonary fibrosis**
- **Pulmonary hypertension** (increased pulmonary vascular resistance)
- **Right ventricular hypertrophy** (present in 9/12 IV abuse deaths)

This pattern of pulmonary vascular disease from IV injection is well-established. Schaiberger et al. (1993 [Ref 10]) documented marked pulmonary hypertension in a truck driver with a 10-year history of inhaling propylhexedrine ("peanut butter methamphetamine") and methamphetamine.

**Pulmonary hypertension from oral use:**
Cameron et al. (1984 [Ref 12]) reported pulmonary hypertension in a 39-year-old woman following 8 years of oral propylhexedrine hydrochloride use as an anorectic — the first documented case of oral-route propylhexedrine causing pulmonary hypertension.

Proposed mechanisms of pulmonary vascular disease: toxic endothelial injury, hypoxic insult, direct vascular spasm, vasculitis, and dysregulation of mediators of vascular tone (Schaiberger et al. 1993 [Ref 10]).

**Other cardiovascular findings documented in cases:**
- Myocardial infarction (Fornazzari et al. 1986 [Ref 11] — documented in literature review)
- Tachycardia/arrhythmia (FDA data [Ref 29]; Horowitz 2024 [Ref 2])
- Severe hypertension (FDA [Ref 21, Ref 29])

### Neurological Toxicity

**Brainstem dysfunction from IV abuse:**
7 cases documented; 2 definite (persistent internuclear ophthalmoplegia, tongue paralysis lasting months) and 5 transient (diplopia within seconds of injection). Preparation method: heating Benzedrex inhaler with HCl, dissolving crystals in water ("stove-top speed") (Fornazzari et al. 1986 [Ref 11]).

**Neurological effects from oral misuse:**
Neurological impairment with associated MRI abnormalities documented in 2024 case (Horowitz et al. 2024 [Ref 2]) — specific MRI findings not available from abstract; likely white matter changes consistent with other stimulant neurotoxicity patterns.

### Psychiatric Toxicity

Psychosis, paranoia, and hallucinations are documented in multiple case series and retrospective reviews (Fornazzari et al. 1986 [Ref 11]; Fernandez & Francis 2012 [Ref 9]; FDA 2021 [Ref 29]). These were recognized as early as 1949 when propylhexedrine replaced amphetamine sulfate (which had been withdrawn partly due to psychosis reports).

### Fatal Injection Site Complications

Perez et al. (1994 [Ref 3]) documented a case of IV propylhexedrine injection into the right internal jugular vein causing massive cervical edema, tracheal displacement, necrotic tissue requiring surgical debridement, progressive renal failure, and ultimately cardiopulmonary arrest and death. This illustrates the severe local tissue toxicity of injecting propylhexedrine solutions.

---

## Harm Reduction

**Published risk reduction evidence:**
No controlled harm reduction trials specific to propylhexedrine exist. The following is derived from clinical case literature and official guidance.

**Route-specific harms:**
- **Inhalation (intended use):** Lowest risk route; no significant systemic absorption at label doses; no documented psychoactive effects; not associated with abuse (Wesson 1986 [Ref 25])
- **Oral ingestion:** Risk of severe cardiovascular and neurological toxicity; documented ICU admissions and deaths
- **IV injection:** Extremely high risk; foreign body granulomas, pulmonary hypertension, tissue necrosis, brainstem dysfunction, sudden death. **No safe intravenous use exists**
- **Smoking:** Documented route per FDA data [Ref 29]; risk profile not characterized in literature

**Emergency response (from FDA guidance [Ref 21]):**
Seek emergency services (911) or contact Poison Control (US: 1-800-222-1222) for: rapid/abnormal heart rate, high blood pressure, chest pain, severe agitation, hallucinations, confusion, or loss of consciousness.

**Contraindications (see Interactions section):**
- MAOI use within 14 days (absolute contraindication)
- Severe cardiovascular disease or uncontrolled hypertension (⚠️ FLAG: not specifically sourced from a published study — class-level contraindication for sympathomimetics)
- Pregnancy (teratogenicity data absent from published literature)

**Testing:**
Standard immunoassay drug screens may yield false-positive methamphetamine results (Thurman et al. 1992 [Ref 19]). GC/MS with ring-fragment ion characterization required to distinguish propylhexedrine from methamphetamine.

---

## Tolerance & Dependence

**Tolerance development:**
Rapidly developing tolerance with repeated use is a class-wide property of norepinephrine-dopamine releasing agents. Seed data states "rapidly develops with prolonged and repeated use" — consistent with the dopamine system downregulation mechanism seen with amphetamine-class stimulants. No propylhexedrine-specific tolerance studies in humans were identified.

**Cross-tolerance:**
Seed data lists cross-tolerance with dopamine and stimulant class — consistent with the shared DAT/NET releasing mechanism. No propylhexedrine-specific cross-tolerance data in published literature.

**Dependence:**
No formal quantitative study of propylhexedrine dependence potential exists despite the WHO Expert Committee review (Fernandez & Francis 2012 [Ref 9]; Wesson 1986 [Ref 25]). Fernandez & Francis (2012 [Ref 9]) reported the **first published case of propylhexedrine dependence**, noting the compound's stimulant effects maintained compulsive use despite awareness of harms. Barbexaclone (propylhexedrine component) dependence has been documented in Europe (Darcin et al. 2010 [Ref 26]).

**Withdrawal:**
No specific characterization of propylhexedrine withdrawal syndrome in published literature. By analogy with amphetamine-class stimulants, withdrawal likely involves fatigue, hypersomnia, depression, and craving. No substance-specific data available — this must be labeled as structural analogy if discussed in the article.

---

## Interactions

### MAOIs (Monoamine Oxidase Inhibitors) — **Contraindicated**
Propylhexedrine is absolutely contraindicated with MAOIs (isocarboxazid, phenelzine, tranylcypromine, selegiline, linezolid) and for 14 days after MAOI discontinuation [web sources; Medscape monograph]. Mechanism: MAOIs prevent monoamine catabolism; propylhexedrine-induced mass monoamine release into MAO-inhibited synapses causes catastrophic norepinephrine accumulation → hypertensive crisis. Serotonin syndrome risk if serotonergic component is sufficient.

**⚠️ FLAG:** This contraindication is class-derived for sympathomimetic releasers, not confirmed in a propylhexedrine-specific published case report. No published case of propylhexedrine + MAOI interaction was found in the literature search.

### Tramadol — **Listed as "Lethal" in seed data**
Tramadol possesses weak serotonin reuptake inhibition and norepinephrine reuptake inhibition properties, as well as opioid receptor activity and seizure threshold reduction (dose-dependent). One FDA adverse event case identified propylhexedrine combined with tramadol (and kratom/mitragynine) resulting in collapse and death [Ref 29]. The interaction mechanism is likely:
1. **Seizure risk amplification:** Both tramadol (serotonin/NE activity, pro-convulsant) and high-dose propylhexedrine (CNS excitation) lower seizure threshold additively
2. **Cardiovascular synergy:** Additive tachycardia and hypertension
3. **Potential serotonergic synergy** if propylhexedrine has serotonin-releasing properties

**⚠️ FLAG:** The seed data labels this interaction "lethal." Published evidence for this specific combination is limited to one FDA case report involving polydrug use (propylhexedrine + tramadol + kratom + other substances). No standalone published case report of propylhexedrine + tramadol as a dyad causing fatality was found in the literature search. The "lethal" severity rating is plausible mechanistically but requires editorial review of source for this classification.

### Kratom (Mitragynine) — Case-documented
Holler et al. (2011 [Ref 1]) documented one fatality with blood propylhexedrine 1.7 mg/L and mitragynine 0.39 mg/L. Medical examiner ruled propylhexedrine toxicity as cause of death; mitragynine may have contributed synergistically (opioid + stimulant combination). This is the **only peer-reviewed case report** of propylhexedrine + kratom fatality.

### Alcohol — **Listed as "Unknown" in seed data**
No published case reports or pharmacological studies examining propylhexedrine + alcohol interaction were identified. Mechanistically, ethanol could attenuate pressor effects (via vasodilation) while simultaneously increasing risk of cardiac arrhythmia. Classification as "unknown" is appropriate; seed data severity rating is not contradicted.

### Other Stimulants
Additive cardiovascular stimulation risk with other sympathomimetics or monoamine releasing agents (cocaine, amphetamine). No propylhexedrine-specific polydrug data in published literature beyond the cases described above.

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | OTC (no prescription required) | Removed from CSA Schedule V in 1991; certain state-level restrictions remain (Alaska, Arizona, Florida, Georgia, Idaho, Kansas, Rhode Island) |
| United Kingdom | Deregulated (unscheduled) | Removed from Misuse of Drugs Act 1971 via 1995 Modification Order |
| Australia | Schedule 4 (prescription-only) | Listed in Poisons Standard |
| Canada | Unscheduled | Previously Schedule V; removed from Controlled Drugs and Substances Act 2022 |
| Germany | Prescription-only | |
| Brazil | Class B1 | Controlled substance |
| International | No international scheduling | Convention on Psychotropic Substances control reversed 1991 |

**Sources:** Web-retrieved legal status data [Ref 23]; Fernandez & Francis 2012 [Ref 9]; Wesson 1986 [Ref 25].

---

## Clinical Trials

**ClinicalTrials.gov search result:** Zero active, completed, or terminated registered trials found for propylhexedrine (search conducted May 2026).

No controlled human pharmacological studies of propylhexedrine have been registered or published. This is a **significant evidence gap**: all human data derives from case reports, adverse event surveillance, and post-market monitoring.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### ⚠️ Safety-Critical Flags Requiring Editorial Review

1. **Receptor binding data (Ki/EC50 absent):** No primary published study provides quantitative binding affinity data for propylhexedrine at NET, DAT, SERT, TAAR1, or adrenergic receptor subtypes. Mechanism of action characterization relies on secondary sources and class pharmacology. The generation agent must not present specific Ki values as if they were published.

2. **Tramadol "lethal" interaction:** Seed data classifies this as "lethal." Published evidence is limited to one FDA FAERS polydrug death case (propylhexedrine + tramadol + kratom + other substances). The interaction is mechanistically plausible (seizure threshold lowering, cardiovascular synergy) but no peer-reviewed case report isolating this dyad was found. **Flag for editorial review before publishing this severity rating.**

3. **Human pharmacokinetic data limited:** The only quantitative PK data in published literature comes from a mouse model (Iven & Feldbusch 1983, PMID 6139756). The 1971 human study (Appel & Sprengard, PMID 5109288) has no available abstract. The estimated human half-life of 4 ± 1.5 hours derives from secondary sources (HandWiki) citing unpublished or translated data. Flag if human PK is presented as definitively established.

4. **CYP enzyme specifics absent:** The specific CYP isoforms responsible for propylhexedrine metabolism are mentioned in secondary sources without citation to a primary study. Generating content about specific CYP enzymes without primary source verification is not supported.

5. **MAOI contraindication source:** The MAOI contraindication is class-derived for sympathomimetic releasing agents, not propylhexedrine-specific. Medscape monograph lists specific MAOI names as contraindicated but no peer-reviewed case report of propylhexedrine + MAOI interaction was found.

6. **Toxicity data note in seed data:** Seed data acknowledges "Inferred from pharmacological class — not sourced from literature. Review recommended." for acute/chronic toxicity ratings. This is consistent with the literature search results — toxicity assessment is primarily derived from case reports rather than systematic toxicological studies.

### Information Gaps (Non-Safety-Critical)

7. **S-isomer pharmacology:** The S-isomer (levopropylhexedrine) is reported as more biologically active, but no published study providing a quantitative comparison of enantiomer pharmacological potency was identified.

8. **Withdrawal characterization:** No published characterization of propylhexedrine-specific withdrawal syndrome exists. Any withdrawal description must be labeled as structural analogy inference from amphetamine-class literature.

9. **Pregnancy and lactation:** No published data on propylhexedrine safety in pregnancy or lactation was identified.

10. **Dose-response for psychoactive effects:** No controlled human study exists. Dose ranges in seed data (threshold 10 mg through heavy 180+ mg) appear to derive from community consensus (Fernandez & Francis 2012 notes abuse doses extractions from inhalers, each containing ~250 mg propylhexedrine liquid). These ranges are plausible but unverified by controlled studies.

11. **Skin/smoking route data:** FDA documents smoking as a route of exposure but no published toxicological characterization of smoked propylhexedrine exists.

12. **Bioavailability by route:** Oral bioavailability ~37% (mouse only); no human IV/oral bioavailability comparison study found.